Recent Updates
Recently added Catalysts

Hexadecasaccharide

Phase 2

Coronary Atherosclerosis | Small molecule | Cardiovascular |Sanofi|Last Updated: Aug 21, 2008

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment1,257

FDA Designations

No designations recorded

Clinical trial landscape

Hexadecasaccharide · 1 trial · 1 indication

Phase 2 1
NCT00123565Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial InfarctionCoronary Atherosclerosis
COMPLETED1,257 Analytics
PHASE2COMPLETED
Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction
Coronary Atherosclerosis
NCT001235651,257
Unlock trial analytics

Study Endpoints

Primary Endpoints

Efficacy: composite of all causes of death, new myocardial infarction, or severe myocardial ischemia requiring urgent repeat target vessel revascularization within 7 days following randomization.

Secondary Endpoints

Safety: Major bleeding according to the criteria of Thrombolysis In Myocardial Infarction study group.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Hexadecasaccharide (SR123781A)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites18

Inclusion Criteria: * A person with a diagnosis of acute coronary syndrome who is scheduled to undergo a PCI within 48 hours. * A person who is of the legal age of 21, who is mentally competent, and who has signed a written informed consent Exclusion Criteria: * A person with known allergy or any...

Countries:United StatesArgentinaAustraliaBelgiumBrazilCanadaChileCzechiaFranceIndiaMexicoNetherlandsPolandPortugalRussiaSouth KoreaSpainTurkey (Türkiye)
Unlock Eligibility Criteria

Frequently asked questions about Hexadecasaccharide

What is Hexadecasaccharide used for?

Hexadecasaccharide, also known as SR123781A, is an investigational small molecule being studied for the treatment of coronary atherosclerosis. It was evaluated in patients with unstable angina or non-ST-segment elevation myocardial infarction, conditions related to coronary artery disease.

Who makes Hexadecasaccharide?

Hexadecasaccharide is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical development for cardiovascular indications.

What phase is Hexadecasaccharide in?

Hexadecasaccharide is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is no longer being tested in active clinical trials.

What clinical trials is Hexadecasaccharide in?

Hexadecasaccharide was studied in a Phase 2 clinical trial with the identifier NCT00123565, titled 'Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction.' The trial enrolled 1,257 participants and has been completed.

Is Hexadecasaccharide the same as SR123781A?

Yes, Hexadecasaccharide is also known as SR123781A. Both names refer to the same investigational drug being developed by Sanofi for the treatment of coronary atherosclerosis.